Skip to Content

Strs Ohio purchases 10,100 Meridian Bioscience, Inc. shares (NASDAQ:VIVO)

Strs Ohio purchases 10,100 Meridian Bioscience, Inc. shares (NASDAQ:VIVO)

The most recent filing that Meridian Bioscience, Inc. made with the Securities and Exchange Commission revealed that during the third quarter, Strs Ohio increased the percentage of the company’s stock that is owned by 61.2%. The institutional investor increased the total number of shares they owned in the company by 26,600 after making additional purchases of 10,100 shares during the relevant period. This brought the total number of shares they owned in the company to 26,600. At the end of the most recent quarter, Strs Ohio had a holding in Meridian Bioscience that was worth $838,000. This accounted for 0.06% of the total company.

The amount of the company’s stock that hedge funds and other institutional investors held in their portfolios was recently adjusted due to recent market events. In the second quarter, Financial Gravity Asset Management Inc. performed a transaction that increased its ownership stake in Meridian Bioscience and brought the total investment cost to approximately $2,668,000. Venture Visionary Partners LLC made a further investment in the amount of $64,000 in Meridian Bioscience during the second quarter of the fiscal year. KBC Group NV purchased Meridian Bioscience for a total price of $113,000 during the second quarter of the fiscal year. During the second quarter, Lazard Asset Management LLC brought its total ownership in Meridian Bioscience to 13,860.7% higher than before. Lazard Asset Management LLC now has 3,909 shares of the company’s stock, with a combined value of $118,000. These shares were acquired as a result of subsequent purchases that amounted to a total of 3,881 additional shares. During the second quarter, First Bank & Trust increased the amount of stock it held in Meridian Bioscience by 57.6%, making this the last and most important point. First Bank & Trust now holds a total of 5,231 shares of the company’s stock, which are currently valued at $159,000 following the acquisition of an additional 1,912 shares during the period. At present, 89.72% of the company’s shares are owned by institutions.

On Monday morning, the price of a share of VIVO stock was $33.66 when trading got underway. 3.63 for the current ratio, 2.46 for the quick ratio, and 0.7 for the debt-to-equity ratio Both the current ratio and the quick ratio are at 3.63, but the quick ratio is at 2.46. The price-to-earnings ratio of the company’s stock is currently sitting at 34.70, and its beta value currently stands at 0.26. The total value of the company’s stock on the market is equivalent to 1.48 billion dollars. The price of the stock’s moving average over the past fifty days is $32.56; over the last two hundred days, it has been $32.36. Throughout its existence, Meridian Bioscience, Inc. experienced both a 52-week low of $19.91 and a 52-week high of $34.38 in its share price.

Meridian Bioscience (NASDAQ: VIVO) disclosed the company’s most recent quarterly profits on November 22nd, making the announcement public. The company’s actual earnings per share generated for the quarter were $0.20, which is $0.05 more than the consensus projection of $0.15 per share. Despite predictions made by analysts that the company would bring in $67.45 million in revenue during the quarter, the actual amount that the company was able to bring in was only $65.68 million. Meridian Bioscience had a return on equity of 16.74% and a net margin of 12.70% for the company overall. Analysts who fol

Tags

Leave a comment

Your email address will not be published. Required fields are marked *